About: Blocking of the CD80/86 axis as a therapeutic approach to prevent progression to more severe forms of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Blocking of the CD80/86 axis as a therapeutic approach to prevent progression to more severe forms of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Blocking of the CD80/86 axis as a therapeutic approach to prevent progression to more severe forms of COVID-19
Creator	Myers, Richard Bonafonte, Irene Gómez, Antonio Julià, Antonio Lladós, Jordi López-Corbeto, Mireia López-Lasanta, María Marsal, Sara Martínez-Mateu, Sergio Rodríguez-Nunez, Iván
Source	ArXiv
abstract	In its more severe forms, COVID-19 progresses towards an excessive immune response, leading to the systemic overexpression of proinflammatory cytokines like IL6, mostly from the infected lungs. This cytokine storm can cause multiple organ damage and death. Consequently, there is a pressing need to identify therapies to treat and prevent severe symptoms during COVID-19. Based on previous clinical evidence, we hypothesized that inhibiting T cell co-stimulation by blocking CD80/86 could be an effective therapeutic strategy against progression to severe proinflammatory states. To support this hypothesis, we performed an analysis integrating blood transcriptional data we generated from rheumatoid arthritis patients treated with abatacept -- a CD80/86 co-stimulation inhibitor -- with the pathological features associated with COVID-19, particularly in its more severe forms. We have found that many of the biological processes that have been consistently associated with COVID-19 pathology are reversed by CD80/86 co-stimulation inhibition, including the downregulation of IL6 production. Also, analysis of previous transcriptional data from blood of SARS-CoV-infected patients showed that the response to abatacept has a very high level of antagonism to that elicited by COVID-19. Finally, analyzing a recent single cell RNA-seq dataset from bronchoalveolar lavage fluid cells from COVID-19 patients, we found a significant correlation along the main elements of the C80/86 axis: CD86+/80+ antigen presenting cells, activated CD4+ T cells and IL6 production. Our in-silico study provides additional support to the hypothesis that blocking of the CD80/CD86 signaling axis may be protective of the excessive proinflammatory state associated with COVID-19 in the lungs.
has issue date	2020-05-20(xsd:dateTime)
has license	arxiv
sha1sum (hex)	7e990c41fed396537707d80a5171eb7ae15c6ef3
resource representing a document's title	Blocking of the CD80/86 axis as a therapeutic approach to prevent progression to more severe forms of COVID-19
resource representing a document's body	covid:7e990c41fed396537707d80a5171eb7ae15c6ef3#body_text
is schema:about of	named entity 'severe' named entity 'integrating' named entity 'multiple' named entity 'severe' named entity 'data' named entity 'SUPPORT' named entity 'PATHOLOGY' named entity 'GENERATED' named entity 'ITS' named entity 'VERY HIGH LEVEL' named entity 'PROGRESSES' named entity 'IS A' named entity 'TO IDENTIFY' named entity 'HAVE' named entity 'PATIENTS' named entity 'INFECTED' named entity 'BRONCHOALVEOLAR LAVAGE FLUID' named entity 'COULD BE' named entity 'COVID-19' named entity 'CLINICAL' named entity 'RECENT' named entity 'DOWNREGULATION' named entity 'CO-STIMULATION' named entity 'AXIS' named entity 'EFFECTIVE' named entity 'ANTAGONISM' named entity 'PREVIOUS' named entity 'HYPOTHESIS' named entity 'RESPONSE TO' named entity 'LEADING' named entity 'SINGLE CELL RNA-SEQ' named entity 'INTEGRATING' named entity 'SIGNIFICANT' named entity 'PRODUCTION' named entity 'lungs' named entity 'signaling' named entity 'proinflammatory' named entity 'blocking' named entity 'systemic' named entity 'inhibition' named entity 'leading' named entity 'biological processes' named entity 'axis' named entity 'production' named entity 'proinflammatory' named entity 'therapeutic' named entity 'patients' named entity 'pathological' named entity 'overexpression' named entity 'CD86' named entity 'excessive' named entity 'CD80' named entity 'biological processes' named entity 'lungs' named entity 'pathology' named entity 'CD86' named entity 'transcriptional' named entity 'IL6' named entity 'antigen presenting cells' named entity 'proinflammatory' named entity 'IL6' named entity 'proinflammatory cytokines' named entity 'co-stimulation' named entity 'COVID-19' named entity 'COVID' named entity 'in-silico' named entity 'CD4+ T cells' named entity 'single cell RNA-seq' named entity 'organ damage' named entity 'SARS' named entity 'correlation' named entity 'COVID-19' named entity 'cytokine storm' named entity 'lungs' named entity 'proinflammatory cytokines' named entity 'abatacept' named entity 'transcriptional' named entity 'CD80'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software